Zydus Cadila gets USFDA nod to market osteoporosis drug; to be manufactured in co's Ahmedabad unit


New Delhi: Drug agency Zydus Cadila has obtained a closing nod from the US well being regulator for Risedronate Sodium delayed-release tablets, used for the therapy of osteoporosis in post-menopausal girls.

The corporate has obtained closing approval from the USFDA to market the tablets within the power of 35 mg in America, Zydus Cadila mentioned in a press release on Thursday.

Consultant picture. PTI

The product might be manufactured on the group’s formulations manufacturing facility at Moraiya, Ahmedabad, it added.

Risedronate alters bone formation and breakdown within the physique. This will sluggish bone loss and will assist stop bone fractures. This medication is used to deal with osteoporosis in girls, attributable to menopause, Zydus Cadila mentioned.

The group now has 218 approvals and has to this point filed over 330 abbreviated new drug purposes (ANDAs) because the graduation of its submitting course of, it added.



Source link

Facebook Comments